[ad_1]
Assenagon Asset Management S.A. trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 72.9% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 41,592 shares of the medical research company’s stock after selling 112,137 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Thermo Fisher Scientific were worth $16,864,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. Bernard Wealth Management Corp. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at about $25,000. CBIZ Investment Advisory Services LLC lifted its position in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after buying an additional 33 shares during the last quarter. Ameriflex Group Inc. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at about $30,000. Anderson Financial Strategies LLC purchased a new stake in shares of Thermo Fisher Scientific during the first quarter valued at about $30,000. Finally, Keystone Global Partners LLC purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $31,000. 89.23% of the stock is owned by hedge funds and other institutional investors.
Thermo Fisher Scientific Trading Down 1.1%
Shares of TMO stock opened at $474.54 on Tuesday. The stock’s fifty day moving average is $472.99 and its two-hundred day moving average is $448.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market capitalization of $179.19 billion, a P/E ratio of 27.45, a PEG ratio of 2.56 and a beta of 0.75. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the previous year, the firm earned $5.37 EPS. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.
Thermo Fisher Scientific Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 9.95%.
Analysts Set New Price Targets
Several equities analysts recently commented on TMO shares. Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research report on Tuesday, July 8th. Scotiabank raised shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price objective for the company in a research report on Friday, July 11th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, September 7th. UBS Group increased their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research report on Thursday, July 24th. Finally, Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Sixteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $588.35.
Get Our Latest Research Report on Thermo Fisher Scientific
Insider Transactions at Thermo Fisher Scientific
In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares of the company’s stock, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company’s stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 in the last quarter. Company insiders own 0.33% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Read More
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link